Loading…
PSHP 2026 Residency Conference has ended
← Back to schedule
Assessment Of The Efficacy Of IV Iron 1500 mg vs. 1000 mg On Hematologic Response
Monday May 18, 2026 1:30pm - 1:50pm EDT
a.Pavilion Hub WEST
Purpose 
The purpose of this retrospective review is to compare hematologic and iron-related responses between traditional 1000 mg iron courses, and high dose courses. The goal is to inform optimal dosing strategies and maximize clinical outcomes.
Methods 
This single center, retrospective study evaluated patients who received IV iron between January 1st 2024 and December 31st 2024 at Thomas Jefferson University. Patients were divided into two arms based on total IV iron dose: 1000 mg or 1500 mg. Exclusion criteria was applied removing comorbidities and incomplete records, with final patients case-control matched on: ferritin, baseline hemoglobin (hgb), age, and gender. The primary outcome was mean change in hgb from baseline to between 4-52 weeks post infusion. Secondary outcomes included changes in relevant iron labs (ferritin, transferrin saturation (TSAT), total iron binding capacity (TIBC), iron, and hematocrit (Hct)) and regression analysis of variable associated with change in hgb greater than the 25th percentile (>P25).  


Results 
From 3,508 patients, 591 met eligibility after exclusions. A random sample of 300 patients (150 per arm) were chart reviewed, with exclusions for missing data yielding 213. After matching 166 patients, 83 in each arm, were used for analysis.  IV iron formulation was the significant demographic, with 76 vs 0 receiving ferric carboxymaltose in 1500 mg vs 1000 mg arms respectively. Mean Hgb increased by 3.4 vs 2.7 g/dL (p=0.002) in the 1500 mg vs 1000 mg arms respectively. Greater improvements in Hct, iron, TSAT, TIBC, and ferritin (p<0.01), were
Moderators
HI
JS

Jeff Sivik, PharmD, BCOP

PGY2 Oncology RPD & Adult Oncology Clinical Pharmacy Supervisor, Penn State Health Milton S. Hershey Medical Center

avatar for Kristin Wheatley, PharmD, BCOP
Speakers
MC

Morgan Cherry

PGY1, Thomas Jefferson University Hospital
I attended pharmacy school at Thomas Jefferson University's Jefferson College of Pharmacy in Center City, Philadelphia. After graduation, I began my current role as a PGY1 Pharmacy Resident at Thomas Jefferson University Hospital. My primary interests are solid organ transplant, oncology... Read More →
Monday May 18, 2026 1:30pm - 1:50pm EDT
a.Pavilion Hub WEST
  Oncology

Attendees (19)


Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share

Get help with the event

Contact event planner Event login
View support guides Find upcoming events
Create an event you'd love to attend!
Explore why organizers choose Sched • Success stories
Event App • Event scheduling • Event registration • Event ticketing • Sched forms • Call for papers • Badges • Conferences
© 2026. SCHED LLC - All rights reserved - Helping events since 2008
Conference Scheduling Software • Privacy • Terms
Share Modal

Share this link via

Or copy link